We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi
News

Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi

Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi
News

Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Patent Application Licensed to RXi Pharmaceuticals Issues in Australia with Broad Claims to Expressed RNAi"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RXi Pharmaceuticals Corporation has announced the grant of an Australian patent issued to the University of Massachusetts Medical School covering in vivo production of small interfering RNA (siRNA) that mediate gene silencing.

The granted claims of the patent cover siRNA molecules and their use in methods for inducing RNA interference of a target gene in mammalian cells in vivo.

RXi has an exclusive license to this patent for specific therapeutic fields and gene targets, including the use of siRNA technology to inhibit the human cytomegalovirus (HCMV), the most common intraocular infection in patients with AIDS; the mutant SOD1 gene shown to cause familial ALS in an animal model; and gene targets associated with type 2 diabetes and obesity.

Craig C. Mello, Ph.D., RXi co-founder and Scientific Advisory Board chairman, and the 2006 Noble Laureate recipient for co-discovering RNAi; and Phillip D. Zamore, Ph.D., Alnylam Pharmaceuticals co-founder and Scientific Advisory Board member; were among the RNAi pioneers authoring this patent.

“This is an excellent example of a patent that offers broad coverage and leverage in the field of RNAi therapeutics,” said Tod Woolf, Ph.D., RXi President and CEO.

“Through our licensing agreement with our founders’ institutions, we have access to many pending and issued patent claims. This technology’s addition further broadens our RNAi intellectual property portfolio. Gaining early intellectual property is particularly gratifying given the conservative climate for patents being issued in the RNAi therapeutics field. We envision that expressed RNAi, while not currently our primary focus, may present future opportunities for RXi,” Woolf added.

Advertisement